SLAM
BCRX icon

Swiss Life Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Swiss Life Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Buy
15,658
+820
+6% +$7.42K ﹤0.01% 1556
2026
Q1 		$141K Buy
+14,838
New +$115K ﹤0.01% 1436

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Swiss Life Asset Management's BCRX Position: Q2 2026 in Review

Swiss Life Asset Management increased its BioCryst Pharmaceuticals (BCRX) stake by 5.5% in Q2 2026, buying an estimated $7.42K and bringing the position to 15,658 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #1556.

Swiss Life Asset Management first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Swiss Life Asset Management held 15,658 shares of BioCryst Pharmaceuticals worth $157K as of Q2 2026.
  • Swiss Life Asset Management bought 820 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $7.42K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1556 holding.
  • Swiss Life Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.